Orphagen secures FDA rare paediatric disease status for OR-449 to treat ACC
The firm is developing the OR-449 for both the adult and paediatric forms of ACC as well as…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 Jan 23
The firm is developing the OR-449 for both the adult and paediatric forms of ACC as well as…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Jan 23
The acquisition builds on a multi-year strategic collaboration between BioNTech and InstaDeep and is expected to add around…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Jan 23
Anima Biotech will get a $42m upfront payment with the possibility of further payments towards research and development…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
10 Jan 23
The acquisition will provide AstraZeneca with access to global rights to baxdrostat, CinCor’s novel aldosterone synthase inhibitor drug…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Jan 23
The FDA designation for the 24-valent PCV vaccine candidate was based on positive topline data results from a…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 Jan 23
The Chinese CRDMO will grant GSK a licence for one preclinical bi-specific T cell engaging antibody and the…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
29 Dec 22
As per the deal, PeptiDream will offer peptide candidates found from PeptiDream’s Peptide Discovery Platform System technology for…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Dec 22
Actemra is a humanised monoclonal antibody indicated for hospitalised adult patients receiving systemic corticosteroids and require supplemental oxygen,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Dec 22
The acquisition will complement Kite’s existing in-house research capabilities and provide Kite with rapid manufacturing processes, Armored CAR…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Dec 22
To be renamed TAK-279 after the completion of the deal, NDI-034858 is being studied for the treatment of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates